Targets › RPT
1 program from 1 company in 2 trials: 2 Phase 4; Infectious disease; next expected readout Aug 2029.
Open in Phaseline: the race on RPT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Affiliated Hospital of Nantong University | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | INH, RIF, RPT | Phase 4 | Latent Tuberculosis Infection (LTBI) | Aug 2029 |
Latent Tuberculosis Infection (LTBI) (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.